Apontis Pharma AG
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
APPH | F
Overview
Corporate Details
- ISIN(s):
- DE000A3CMGM5 (+1 more)
- LEI:
- 894500ETO1J6MR8PDF91
- Country:
- Germany
- Address:
- Alfred-Nobel-Straße 10, 40789 Monheim am Rhein
- Website:
- https://apontis-pharma.de/en/
- Sector:
- Manufacturing
Description
Apontis Pharma AG is a pharmaceutical company that specializes in the development, marketing, and distribution of 'Single Pills'. These are fixed-dose combination drugs that unite two or three active pharmaceutical ingredients into a single tablet. The company's portfolio primarily focuses on treating cardiovascular diseases and other chronic conditions. By simplifying treatment regimens, the Single Pill approach aims to improve patient adherence and therapy outcomes, offering medical and economic benefits to the healthcare system. Apontis Pharma also engages in co-marketing activities for established pharmaceutical products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-09-20 07:30 |
APONTIS PHARMA announces cooperation to launch new Single Pill in Germany
|
English | 9.0 KB | ||
| 2022-09-01 07:30 |
APONTIS PHARMA: SECURE study and START study add-on analysis confirm superior e…
|
English | 12.2 KB | ||
| 2022-08-11 07:30 |
APONTIS PHARMA expands profitable positioning in first half of 2022 full-year …
|
English | 33.4 KB | ||
| 2022-08-11 00:00 |
H122 Results Presentation (EN)
|
German | 2.2 MB | ||
| 2022-08-11 00:00 |
H122 Results Presentation
|
English | 2.2 MB | ||
| 2022-08-11 00:00 |
Half-yearly financial statements 2022
|
English | 389.6 KB | ||
| 2022-07-22 00:00 |
Konzernabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
|
German | 323.7 KB | ||
| 2022-07-19 07:30 |
APONTIS PHARMA and Midas Pharma agree on further development partnership for th…
|
English | 12.2 KB | ||
| 2022-07-06 07:30 |
APONTIS PHARMA rolls out new Single Pill for secondary prophylaxis
|
English | 10.2 KB | ||
| 2022-06-23 07:30 |
APONTIS PHARMA AG: Notice according to Article 2 paragraph 1 of Delegated Regul…
|
English | 11.1 KB | ||
| 2022-05-25 07:30 |
APONTIS PHARMA launches two new single pills - medium-term revenue potential of…
|
English | 10.0 KB | ||
| 2022-05-12 15:00 |
APONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all age…
|
English | 9.7 KB | ||
| 2022-05-10 07:30 |
APONTIS PHARMA continues strong profitable growth in Q1 2022
|
English | 33.4 KB | ||
| 2022-05-10 00:00 |
3M22 Unaudited Results (EN)
|
German | 1.3 MB | ||
| 2022-05-10 00:00 |
3M22 Unaudited Results
|
English | 1.3 MB |
Automate Your Workflow. Get a real-time feed of all Apontis Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Apontis Pharma AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Apontis Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-14 | Milz, Thomas | Board | Buy | None | 8,960.00 EUR |
| 2024-05-14 | be executive GmbH | Close relation | Buy | None | 8,880.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 10,128.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 3,396.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 1,692.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 1,688.00 EUR |
| 2023-05-05 | Reineke, Silke | Close relation | Buy | None | 36,625.00 EUR |
| 2023-05-05 | Milz, Thomas | Board | Buy | None | 14,360.00 EUR |
Peer Companies
